Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Cash (2016 - 2025)

Historic Change in Cash for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $27.9 million.

  • Bio-Techne's Change in Cash rose 37942.15% to $27.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.7 million, marking a year-over-year decrease of 10984.88%. This contributed to the annual value of $10.4 million for FY2025, which is 13611.88% up from last year.
  • Bio-Techne's Change in Cash amounted to $27.9 million in Q4 2025, which was up 37942.15% from -$17.2 million recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's Change in Cash ranged from a high of $53.3 million in Q2 2023 and a low of -$51.0 million during Q1 2022
  • Over the past 5 years, Bio-Techne's median Change in Cash value was $4.6 million (recorded in 2022), while the average stood at $367650.0.
  • In the last 5 years, Bio-Techne's Change in Cash surged by 50030.94% in 2021 and then tumbled by 312278.26% in 2023.
  • Over the past 5 years, Bio-Techne's Change in Cash (Quarter) stood at $15.5 million in 2021, then plummeted by 103.7% to -$575000.0 in 2022, then plummeted by 3122.78% to -$18.5 million in 2023, then surged by 46.08% to -$10.0 million in 2024, then skyrocketed by 379.42% to $27.9 million in 2025.
  • Its Change in Cash stands at $27.9 million for Q4 2025, versus -$17.2 million for Q3 2025 and $21.5 million for Q2 2025.